

Hossein Jadvar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6919662/publications.pdf>

Version: 2024-02-01

141
papers

5,154
citations

101384

36
h-index

95083

68
g-index

145
all docs

145
docs citations

145
times ranked

5881
citing authors

#	ARTICLE	IF	CITATIONS
1	Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. <i>Journal of Nuclear Medicine</i> , 2022, 63, 59-68.	2.8	61
2	Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2300-2309.	3.3	20
3	Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1836-1843.	2.8	5
4	Management Impact of Metachronous Oligometastatic Disease Identified on 18F-Fluciclovine (Axumin [®]) PET/CT in Biochemically Recurrent Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2022, 24, 920-927.	1.3	2
5	Molecular Imaging Assessment of Androgen Deprivation Therapy in Prostate Cancer. <i>PET Clinics</i> , 2022, 17, 389-397.	1.5	2
6	SNMMI/ACR/ASNC/SCMR joint credentialing statement for cardiac PET/MRI. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2022, 24, .	1.6	1
7	Role of ¹⁸ F-Fluciclovine and Prostate-Specific Membrane Antigen PET/CT in Guiding Management of Oligometastatic Prostate Cancer: <i>AJR</i> Expert Panel Narrative Review. <i>American Journal of Roentgenology</i> , 2021, 216, 851-859.	1.0	13
8	PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1803-1811.	1.2	24
9	Competitive Advantage of PSMA Theranostics in Prostate Cancer. <i>Radiology</i> , 2021, 299, 261-263.	3.6	3
10	Targeted α -therapy in non-prostate malignancies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 49, 47-53.	3.3	8
11	Low-count whole-body PET with deep learning in a multicenter and externally validated study. <i>Npj Digital Medicine</i> , 2021, 4, 127.	5.7	34
12	Management Impact of 68Ga-DOTATATE PET/CT in Neuroendocrine Tumors. <i>Nuclear Medicine and Molecular Imaging</i> , 2021, 55, 31-37.	0.6	9
13	Salvage Therapies After 18F-Fluciclovine Detected Prostate Cancer Recurrences. <i>Clinical Nuclear Medicine</i> , 2020, 45, 668-671.	0.7	3
14	Invited Commentary: Nuclear Theranostics—The Path Forward. <i>Radiographics</i> , 2020, 40, 1741-1742.	1.4	1
15	Single Institution Patterns of Management of (18)F-Fluciclovine-detected Prostate Cancer Recurrences. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, E62-E63.	0.4	0
16	Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria. <i>Theranostics</i> , 2020, 10, 3254-3262.	4.6	15
17	Targeted α -Therapy in Cancer Management: Synopsis of Preclinical and Clinical Studies. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2020, 35, 475-484.	0.7	17
18	Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 1963-1996.	0.8	107

#	ARTICLE	IF	CITATIONS
19	Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment. <i>Journal of Nuclear Medicine</i> , 2020, 61, 552-562.	2.8	10
20	Prostate Cancer Lymphangitic Pulmonary Carcinomatosis. <i>Clinical Nuclear Medicine</i> , 2020, 45, 727-729.	0.7	0
21	Treatment Response Assessment of Skeletal Metastases in Prostate Cancer with ¹⁸ F-NaF PET/CT. <i>Nuclear Medicine and Molecular Imaging</i> , 2019, 53, 247-252.	0.6	12
22	¹⁸ F-fluciclovine PET-CT and ⁶⁸ Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. <i>Lancet Oncology</i> , The, 2019, 20, 1286-1294.	5.1	338
23	Preclinical evaluation of a ⁶⁴ Cu-labeled disintegrin for PET imaging of prostate cancer. <i>Amino Acids</i> , 2019, 51, 1569-1575.	1.2	4
24	Gallium-68â€“Labeled Prostate-Specific Membrane Antigenâ€“11 PET/CT of Prostate and Nonprostate Cancers. <i>American Journal of Roentgenology</i> , 2019, 213, 286-299.	1.0	7
25	Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with ¹⁸ F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1524-1530.	2.8	25
26	¹⁸ F-Fluciclovine PET/CT Detection of Recurrent Prostate Carcinoma in Patients With Serum PSA â‰¥ 1 ng/mL After Definitive Primary Treatment. <i>Clinical Nuclear Medicine</i> , 2019, 44, e128-e132.	0.7	37
27	A review of prostate cancer imaging, positron emission tomography, and radiopharmaceutical-based therapy. <i>Canadian Urological Association Journal</i> , 2019, 14, 130-138.	0.3	3
28	Value proposition of PSMA-targeted Î±â€“particle radioligand therapy in metastatic prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 8-10.	3.3	4
29	Management of Primary Osseous Spinal Tumors with PET. <i>PET Clinics</i> , 2019, 14, 91-101.	1.5	14
30	Editorial Comment. <i>Journal of Urology</i> , 2019, 202, 420-421.	0.2	0
31	Reply: Staging, Restaging, and Treatment Response Assessment in Lymphomas: What We Should Know. <i>Journal of Nuclear Medicine</i> , 2018, 59, 715-716.	2.8	0
32	Radiotheranostics in Cancer Diagnosis and Management. <i>Radiology</i> , 2018, 286, 388-400.	3.6	91
33	Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors. <i>Molecular Imaging and Biology</i> , 2018, 20, 501-509.	1.3	67
34	¹⁸ F-NaF/ ²²³ RaCl ₂ theranostics in metastatic prostate cancer: treatment response assessment and prediction of outcome. <i>British Journal of Radiology</i> , 2018, 91, 20170948.	1.0	10
35	PSMA PET: Transformational Change in Prostate Cancer Management?. <i>Journal of Nuclear Medicine</i> , 2018, 59, 228-229.	2.8	11
36	Incidental Detection of Meningioma by ¹⁸ F-FMAU PET/CT in a Patient With Suspected Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2018, 43, e245-e246.	0.7	3

#	ARTICLE	IF	CITATIONS
37	PET in the Diagnostic Management of Soft Tissue Sarcomas of Musculoskeletal Origin. PET Clinics, 2018, 13, 609-621.	1.5	31
38	Applications of PET/CT and PET/MR Imaging in Primary Bone Malignancies. PET Clinics, 2018, 13, 623-634.	1.5	47
39	Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases. Clinical Nuclear Medicine, 2018, 43, e226-e231.	0.7	20
40	Clinical Nononcologic Applications of PET/CT and PET/MRI in Musculoskeletal, Orthopedic, and Rheumatologic Imaging. American Journal of Roentgenology, 2018, 210, W245-W263.	1.0	37
41	Point: The Existential Threat to Nuclear Medicine. Journal of the American College of Radiology, 2018, 15, 384-386.	0.9	3
42	Oligometastatic Prostate Cancer: Molecular Imaging and Clinical Management Implications in the Era of Precision Oncology. Journal of Nuclear Medicine, 2018, 59, 1338-1339.	2.8	13
43	PSMA Theranostics: Current Status and Future Directions. Molecular Imaging, 2018, 17, 153601211877606.	0.7	150
44	ACR and SNMMI Joint Credentialing Statement for PET/MRI of the Body. Journal of Nuclear Medicine, 2017, 58, 1174-1176.	2.8	8
45	Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment. American Journal of Roentgenology, 2017, 209, 277-288.	1.0	68
46	SNMMI Comment on the 2016 Society of Surgical Oncology "Choosing Wisely" Recommendation on the Use of PET/CT in Colorectal Cancer. Journal of Nuclear Medicine, 2017, 58, 11-12.	2.8	3
47	Science to Practice: Does FDG Differentiate Morphologically Unstable from Stable Atherosclerotic Plaque?. Radiology, 2017, 283, 1-3.	3.6	14
48	Future cancer research priorities in the USA: a Lancet Oncology Commission. Lancet Oncology, The, 2017, 18, e653-e706.	5.1	153
49	Appropriate Use Criteria for ¹⁸ F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease. Journal of Nuclear Medicine, 2017, 58, 2026-2037.	2.8	78
50	Highlights of articles published in annals of nuclear medicine 2016. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1928-1933.	3.3	3
51	Multimodal imaging in focal therapy planning and assessment in primary prostate cancer. Clinical and Translational Imaging, 2017, 5, 199-208.	1.1	2
52	The Use of Imaging in the Prediction and Assessment of Cancer Treatment Toxicity. Diagnostics, 2017, 7, 43.	1.3	3
53	Prostate-specific antigen and prostate-specific antigen kinetics in predicting 18F-sodium fluoride positron emission tomography-computed tomography positivity for first bone metastases in patients with biochemical recurrence after radical prostatectomy. World Journal of Nuclear Medicine, 2017, 16, 229-236.	0.3	4
54	Imaging of Glycolysis with 18F-FDG PET. , 2017, , 87-94.		0

#	ARTICLE	IF	CITATIONS
55	Effect of Androgen on Normal Biodistribution of [18F]-2- ¹⁸ F-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in Athymic Non-tumor-bearing Male Mice. <i>Anticancer Research</i> , 2017, 37, 475-480.	0.5	1
56	Radiotheranostics in Prostate Cancer: Introduction and Overview. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1S-2S.	2.8	5
57	Is There Use for FDG-PET in Prostate Cancer?. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 502-506.	2.5	128
58	PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 25S-29S.	2.8	38
59	Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 19S-24S.	2.8	30
60	Duplex Doppler sonography: is there clinical relevance to elevated renal vein velocity in kidney transplants?. <i>Clinical Imaging</i> , 2016, 40, 1237-1245.	0.8	3
61	Update on advances in molecular PET in urological oncology. <i>Japanese Journal of Radiology</i> , 2016, 34, 470-485.	1.0	31
62	Targeted Radionuclide Therapy: Practical Applications and Future Prospects. <i>Biomarkers in Cancer</i> , 2016, 8s2, BIC.S31804.	3.6	42
63	Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer. <i>Abdominal Radiology</i> , 2016, 41, 889-898.	1.0	13
64	Targeted Prostate Gland Biopsy With Combined Transrectal Ultrasound, mpMRI, and 18F-FMAU PET/CT. <i>Clinical Nuclear Medicine</i> , 2015, 40, e426-e428.	0.7	11
65	Prognostic Utility of PET in Prostate Cancer. <i>PET Clinics</i> , 2015, 10, 255-263.	1.5	5
66	Association of Overall Survival with Glycolytic Activity of Castrate-Resistant Prostate Cancer Metastases. <i>Radiology</i> , 2015, 274, 624-625.	3.6	14
67	PSMA PET in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1131-1132.	2.8	46
68	One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2015, 30, 195-199.	0.7	34
69	American College of Radiology and Society of Nuclear Medicine and Molecular Imaging Joint Credentialing Statement for PET/MR Imaging: Brain. <i>Journal of Nuclear Medicine</i> , 2015, 56, 642-645.	2.8	10
70	Sodium 18F-Fluoride PET/CT of Bone, Joint, and Other Disorders. <i>Seminars in Nuclear Medicine</i> , 2015, 45, 58-65.	2.5	87
71	Positron Emission Tomography in Prostate Cancer: Summary of Systematic Reviews and Meta-Analyses. <i>Tomography</i> , 2015, 1, 18-22.	0.8	28
72	Imaging Cellular Proliferation in Prostate Cancer with Positron Emission Tomography. <i>Asia Oceania Journal of Nuclear Medicine and Biology</i> , 2015, 3, 72-6.	0.1	6

#	ARTICLE	IF	CITATIONS
73	SNMMI Leadership Update: Developing Evidence-Based Appropriate Use Criteria under the Protecting Access to Medicare Act of 2014. <i>Journal of Nuclear Medicine</i> , 2015, 56, 20N.	2.8	3
74	The SNMMI and EANM Practice Guideline for Tele-Nuclear Medicine 2.0. <i>Journal of Nuclear Medicine Technology</i> , 2014, 42, 15-19.	0.4	9
75	Competitive advantage of PET/MRI. <i>European Journal of Radiology</i> , 2014, 83, 84-94.	1.2	149
76	SNMMI Comment on ASCO 2013 "Choosing Wisely" Recommendation on Use of PET/CT in Recurrent Cancer Surveillance. <i>Journal of Nuclear Medicine</i> , 2014, 55, 699-700.	2.8	2
77	Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 4, 580-601.	1.0	55
78	Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 5-10.	3.3	137
79	Baseline ¹⁸ F-FDG PET/CT Parameters as Imaging Biomarkers of Overall Survival in Castrate-Resistant Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1195-1201.	2.8	110
80	Molecular Imaging of Prostate Cancer with PET. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1685-1688.	2.8	74
81	Targeted α -Particle Therapy of Bone Metastases in Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2013, 38, 966-971.	0.7	46
82	The SNMMI Practice Guideline for Therapy of Thyroid Disease with ¹³¹ I 3.0. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1633-1651.	2.8	229
83	Prospective Evaluation of 18F-NaF and 18F-FDG PET/CT in Detection of Occult Metastatic Disease in Biochemical Recurrence of Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2012, 37, 637-643.	0.7	125
84	Preservation of retinotopic map in retinal degeneration. <i>Experimental Eye Research</i> , 2012, 98, 88-96.	1.2	29
85	Molecular Imaging of Prostate Cancer: PET Radiotracers. <i>American Journal of Roentgenology</i> , 2012, 199, 278-291.	1.0	95
86	Hepatocellular Carcinoma and Gastroenteropancreatic Neuroendocrine Tumors: Potential Role of Other Positron Emission Tomography Radiotracers. <i>Seminars in Nuclear Medicine</i> , 2012, 42, 247-254.	2.5	23
87	[¹⁸ F]-2-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (¹⁸ F-FMAU) in Prostate Cancer: Initial Preclinical Observations. <i>Molecular Imaging</i> , 2012, 11, 7290.2012.00004.	0.7	12
88	Can Choline PET Tackle the Challenge of Imaging Prostate Cancer?. <i>Theranostics</i> , 2012, 2, 331-332.	4.6	8
89	[18F]-2'-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in prostate cancer: initial preclinical observations. <i>Molecular Imaging</i> , 2012, 11, 426-32.	0.7	9
90	Prostate Cancer: PET with ¹⁸ F-FDG, ¹⁸ F- or ¹¹ C-Acetate, and ¹⁸ F- or ¹¹ C-Choline. <i>Journal of Nuclear Medicine</i> , 2011, 52, 81-89.	2.8	288

#	ARTICLE	IF	CITATIONS
91	Colonic FDG Uptake Pattern in Subjects Receiving Oral Contrast With No Known or Suspected Colonic Disease. <i>Clinical Nuclear Medicine</i> , 2011, 36, 754-756.	0.7	6
92	FDG PET/CT Demonstration of Pancreatic Metastasis From Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2011, 36, 961-962.	0.7	12
93	ACRâ€™ASTRO Practice Guideline for the Performance of Therapy With Unsealed Radiopharmaceutical Sources. <i>Clinical Nuclear Medicine</i> , 2011, 36, e72-e80.	0.7	5
94	Prostate Cancer. <i>Methods in Molecular Biology</i> , 2011, 727, 265-290.	0.4	8
95	The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo. <i>Prostate</i> , 2010, 70, 1359-1370.	1.2	21
96	Influence of Trigger PSA and PSA Kinetics on ¹¹ C-Choline PET/CT Detection Rate in Patients with Biochemical Relapse After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2010, 51, 498.2-499.	2.8	0
97	Evolving Cardiac Conduction Phenotypes in Developing Zebrafish Larvae: Implications to Drug Sensitivity. <i>Zebrafish</i> , 2010, 7, 325-331.	0.5	24
98	Molecular Imaging of Prostate Cancer: A Concise Synopsis. <i>Molecular Imaging</i> , 2009, 8, 7290.2009.00010.	0.7	22
99	¹⁸ F-FDG Uptake in Lung, Breast, and Colon Cancers: Molecular Biology Correlates and Disease Characterization. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1820-1827.	2.8	203
100	Molecular imaging of prostate cancer with ¹⁸ F-fluorodeoxyglucose PET. <i>Nature Reviews Urology</i> , 2009, 6, 317-323.	1.9	73
101	FDG PET in Prostate Cancer. <i>PET Clinics</i> , 2009, 4, 155-161.	1.5	46
102	Role of Imaging in Prostate Cancer. <i>PET Clinics</i> , 2009, 4, 135-138.	1.5	14
103	Preface. <i>PET Clinics</i> , 2009, 4, ix.	1.5	0
104	Molecular imaging of prostate cancer: a concise synopsis. <i>Molecular Imaging</i> , 2009, 8, 56-64.	0.7	8
105	Evaluation by ¹⁸ F-FDG-PET of patients with anal squamous cell carcinoma. <i>Hellenic Journal of Nuclear Medicine</i> , 2009, 12, 26-9.	0.2	17
106	[F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland. <i>Annals of Nuclear Medicine</i> , 2008, 22, 787-793.	1.2	33
107	[F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2008, 13, 42-47.	1.0	67
108	A systematic review on diagnostic accuracy of CT-based detection of significant coronary artery disease. <i>European Journal of Radiology</i> , 2008, 65, 449-461.	1.2	156

#	ARTICLE	IF	CITATIONS
109	Choline autoradiography of human prostate cancer xenograft: effect of castration. <i>Molecular Imaging</i> , 2008, 7, 147-52.	0.7	9
110	[F-18]Fluorodeoxyglucose Positron Emission Tomography and Positron Emission Tomography. <i>Journal of Computer Assisted Tomography</i> , 2007, 31, 223-228.	0.5	66
111	Adenocarcinoma in an Indiana Pouch on PET-CT. <i>Clinical Nuclear Medicine</i> , 2007, 32, 57-58.	0.7	4
112	PET and PET/CT in Pediatric Oncology. <i>Seminars in Nuclear Medicine</i> , 2007, 37, 316-331.	2.5	115
113	Actinomycosis Mimicking Anastomotic Recurrent Esophageal Cancer on PET-CT. <i>Clinical Nuclear Medicine</i> , 2006, 31, 646-647.	0.7	19
114	2-Deoxy-2-[F-18]Fluoro-d-Glucoseâ€“Positron Emission Tomography/Computed Tomography Imaging Evaluation of Esophageal Cancer. <i>Molecular Imaging and Biology</i> , 2006, 8, 193-200.	1.3	22
115	FDG PET-CT Demonstration of Sjogren??s Sialoadenitis. <i>Clinical Nuclear Medicine</i> , 2005, 30, 698-699.	0.7	18
116	PET in pediatric diseases. <i>Radiologic Clinics of North America</i> , 2005, 43, 135-152.	0.9	28
117	Glucose metabolism of human prostate cancer mouse xenografts. <i>Molecular Imaging</i> , 2005, 4, 91-7.	0.7	25
118	Musculoskeletal system. <i>Seminars in Nuclear Medicine</i> , 2004, 34, 254-261.	2.5	36
119	The reproductive tract. <i>Seminars in Nuclear Medicine</i> , 2004, 34, 262-273.	2.5	10
120	Fusion Positron Emission Tomographyâ€“Computed Tomography Demonstration of Epidural Metastases. <i>Clinical Nuclear Medicine</i> , 2004, 29, 39-40.	0.7	7
121	Yosemite, California. <i>American Journal of Roentgenology</i> , 2003, 181, 302-302.	1.0	0
122	Advances in Imaging of Nonthyroid Endocrine Neoplasms. <i>Problems in General Surgery</i> , 2003, 20, 11-20.	0.2	1
123	Cancun, Mexico. <i>American Journal of Roentgenology</i> , 2003, 181, 1092-1092.	1.0	0
124	FDG PET in suspected recurrent and metastatic prostate cancer. <i>Oncology Reports</i> , 2003, 10, 1485-8.	1.2	43
125	Incidental Colonic Fluorodeoxyglucose Uptake: Correlation with Colonoscopic and Histopathologic Findings. <i>Radiology</i> , 2002, 224, 783-787.	3.6	187
126	Pharmacologic Interventions in Nuclear Radiology: Indications, Imaging Protocols, and Clinical Results. <i>Radiographics</i> , 2002, 22, 477-490.	1.4	32

#	ARTICLE	IF	CITATIONS
127	Joshua Tree National Park, California. American Journal of Roentgenology, 2002, 178, 110-110.	1.0	0
128	â€œAlas, Poor Yorick!â€ American Journal of Roentgenology, 2002, 178, 178-178.	1.0	2
129	Death Valley, California. American Journal of Roentgenology, 2002, 179, 1244-1244.	1.0	1
130	Diagnostic utility of FDG PET in multiple myeloma. Skeletal Radiology, 2002, 31, 690-694.	1.2	89
131	Procedure guideline for telenuclear medicine 1.0. Journal of Nuclear Medicine, 2002, 43, 1410-3.	2.8	6
132	Room with a View (North Coast of Aruba). American Journal of Roentgenology, 2001, 177, 806-806.	1.0	0
133	Raw and Ripe. American Journal of Roentgenology, 2001, 177, 886-886.	1.0	0
134	Gone Fishing. American Journal of Roentgenology, 2000, 175, 140-140.	1.0	0
135	The Effect of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography on the Management of Cutaneous Malignant Melanoma. Clinical Nuclear Medicine, 2000, 25, 48.	0.7	43
136	SPECT and PET in the Evaluation of Coronary Artery Disease. Radiographics, 1999, 19, 915-926.	1.4	24
137	Evaluation of Rare Tumors with [F-18]Fluorodeoxyglucose Positron Emission Tomography. Molecular Imaging and Biology, 1999, 2, 153-158.	0.3	53
138	Effect of Atropine and Sincalide on the Intestinal Uptake of F-18 Fluorodeoxyglucose. Clinical Nuclear Medicine, 1999, 24, 965.	0.7	23
139	Utility of a stimulus artifact suppressor for transesophageal pacing. American Journal of Cardiology, 1990, 65, 393-394.	0.7	5
140	A reusable perfusion supporting tissue-mimicking material for ultrasound hyperthermia phantoms. Medical Physics, 1990, 17, 380-390.	1.6	26
141	Prostate-specific Membrane Antigen PET: Standard Imaging in Prostate Cancer. Radiology, 0, , .	3.6	0